BACKGROUND

Technical Field

The present disclosure relates to a medical ointment containing paeonol and panthenol and a pharmaceutical use thereof, and more particularly, to a medical ointment of a novel combination containing paeonol and panthenol and a pharmaceutical use thereof, the medical ointment exhibiting excellent effects in suppressing pruritus and pain while effectively treating inflammation, by solving the problems of wound treatment ointments of the related art.

Description of Related Technology

Inflammation is typically characterized by a localized tissue response to, for example, invasion of microorganisms, specific antigens, damaged cells, or physical or chemical factors, and an inflammatory response is a normally protective mechanism that not only initiates the treatment of tissues, but also destroy, dilute, or sequester both detrimental agents and damaged tissues. Such inflammation may arise from physical trauma, infection, some chronic diseases (for example, autoimmune diseases such as psoriasis and rheumatoid arthritis) or chemical or physiological responses to external stimuli (for example, part of an allergic reaction). Inflammatory mediators can increase blood flow and dilation of local blood vessels, resulting in redness and heat, effusion of body fluids, often causing local edema, migration of white blood cells to the inflammatory site, and pain, and many diseases are characterized by abnormal tissue damage inflammation and caused thereby. These conditions are typically characterized by the activation of immune defense mechanisms, which can result in more detrimental than beneficial effects on the host, and are generally associated with varying degrees of tissue redness or hyperemia, swelling, high fever, pain, itching, cell death, tissue destruction, cell proliferation, or loss of function, and examples thereof include inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, psoriasis, glomerulonephritis, and transplant rejection. These inflammatory changes are triggered by a series of cellular and biochemical events involving cells such as neutrophils, monocytes, macrophages, and lymphocytes, along with inflammatory mediators such as vasoactive amines, cytokines, complement factors, and reactive oxygen species, and, most of all, inflammation plays an important role in the wound healing process. Thus, wounds such as cuts, and burns can be classified as conditions associated with inflammation. It is generally considered in the art that anti-inflammatory drugs should not act directly on open wounds since they may be detrimental to the progress of wound healing.

In consideration of the above points, conventionally developed and provided ointments for the treatment of wounds, such as cuts, or burns include Fucidin™, Composite Madecassol™ and Madecassol Care™.

NON-PATENT DOCUMENTS

(Non-Patent Document 1) Non-Patent Document 1: Br J Pharmacol 2003 July; 139(6):1146-52 Anti-inflammatory and analgesic effects of paeonol in carrageenan-evoked thermal hyperalgesia(Non-Patent Document 2) Non-Patent Document 2: Artificial Cells, Nanomedicine, and Biotechnology: An International Journal Volume 46, 2018—Issue sup1: Supplement 1 Beneficial anti-inflammatory effect of paeonol self-microemulsion-loaded colon-specific capsules on experimental ulcerative colitis rats(Non-Patent Document 3) Non-Patent Document 3: Evidence-Based Complementary and Alternative Medicine Volume 2012, Article ID837513, 12 pages Anti-Inflammatory and Anticoagulative Effects of Paeonol on LPS-Induced Acute Lung Injury in Rats(Non-Patent Document 4) Non-Patent Document 4: Front Pharmacol, 20 Nov. 2018 Paeonol Attenuated Inflammatory Response of Endothelial Cells via Stimulating Monocytes-Derived Exosomal MicroRNA-223(Non-Patent Document 5) Non-Patent Document 5: TRADITIONAL CHINESE MEDICINE AND NEURAL REGENERATION Year: 2013|Volume: 8|Issue: 18|Page: 1637-1643 Paeonol attenuates inflammation-mediated neurotoxicity and microglial activation(Non-Patent Document 6) Non-Patent Document 6: Frontiers in Physiology March 2017, Volume 8 Article 193 Prevention of Bleomycin-induced Pulmonary Inflammation and Fibrosis in Mice by Paeonol(Non-Patent Document 7) Non-Patent Document 7: MOLECULAR MEDICINE REPORTS 19: 3217-3229, 2019 Paeonol inhibits the development of 1_chloro_2,4_dinitrobenzene_induced atopic dermatitis via mast and T cells in BALB/c mice(Non-Patent Document 8) Non-Patent Document 8: Oncotarget 2017; 8:27093-27104 Paeonol suppresses solar ultraviolet-induced skin inflammation by targeting T-LAK cell-originated protein kinase

SUMMARY

The present disclosure provides a novel pharmaceutical composition that effectively treats inflammation while showing excellent effects on the suppression of pruritus and pain by recognizing the problem of showing little effect on itching and pain caused by the inflammatory reaction due to the focus only on the treatment of clean wounds in the case of the prior art, such as Madecassol™ or Fucidin™, and in response, addressing the cut treatment ointments of the related art.

The present disclosure also provides a pharmaceutical use of a novel pharmaceutical composition that effectively treats inflammation while showing excellent effects in suppressing pruritus and pain.

The present disclosure also provides a method of easily manufacturing a novel pharmaceutical composition having such excellent functionalities described above.

In addition, the present disclosure is not limited to these technical problems, and furthermore, the present disclosure also provides other objectives that can be easily derived by those skilled in the art from the general description of the present specification in addition to the objectives described above.

The purpose of the present disclosure is to provide ointments of a new combination of paeonol with other specific pharmaceutical compositions, based on the fact that paeonol is known to be effective in relieving local pain due to its anti-inflammatory effect, which is identified through many animal experiments, in which the ointments are very effective in relieving itching and pain during treatment along with the treatment of clean wounds.

According to one or more embodiments, a composition for external application includes, as an active ingredient, paeonol and panthenol.

The term “paeonol” used herein includes derivatives thereof and pharmaceutically acceptable salts thereof, and likewise, the term “panthenol” used herein includes derivatives thereof and pharmaceutically acceptable salts thereof.

Accordingly, the composition for external application of the present disclosure may include one or more selected from paeonol, derivatives thereof, and pharmaceutically acceptable salts thereof, and one or more selected from panthenol, derivatives thereof, and pharmaceutically acceptable salts thereof.

In an embodiment of the present disclosure, the composition for external application may include paeonol in an amount of 0.1% (w/w) to 3% (w/w), 0.5% (w/w) to 2% (w/w), or 1% (w/w) to 2% (w/w), based on the total weight of the composition for external application.

In an embodiment of the present disclosure, the composition for external application may include panthenol in an amount of 0.5% (w/w) to 6% (w/w), 2% (w/w) to 5% (w/w), or 4% (w/w) to 5% (w/w), based on the total weight of the composition for external application.

In an embodiment of the present disclosure, the composition for external application may further include at least one selected fromCentella asiatica, coenzyme Q10, neomycin sulfate, and pharmaceutically acceptable salts of these, in an amount of 4% (w/w) to 7% (w/w), or 5% (w/w) to 6% (w/w) based on the total weight of the composition for external application.

In some embodiments, based on the total weight of the composition for external application, the amount ofCentella asiaticamay be from 0.5% (w/w) to 1.5% (w/w), or 1% (w/w), the amount of Q10 may be from 0.5% (w/w) to 1.5% (w/w), or 1% (w/w), and the amount of neomycin sulfate may be from 3% (w/w) to 4% (w/w), or 3.5% (w/w).

The composition for external application of the present disclosure may be provided for treatment of a wound, inflammation inhibition, pruritus reduction, and/or pain relief.

In an embodiment of the present disclosure, the wound may be abrasions, scrapes, incisions, lacerations, skin punctures, tears, bruises, scars or blisters, or wounds associated with any of these.

In an embodiment of the present disclosure, the wound may be a wound causing itching and pain.

On the other hand, the present disclosure provides a method of treating wounds and alleviating pruritus, including applying the composition for external application on skin wounds of a subject.

The present disclosure also provides the use of the composition for external application as described above for the manufacture of a medicament for the treatment of skin wounds and/or alleviation of pruritus.

In relation to the medical ointment of a novel combination containing paeonol and panthenol of the present disclosure configured as described above, specific ingredients that are effective in relieving local pain are combined with ingredients that have other effects in a certain ratio so that the problems of conventional wound healing ointments are addressed to effectively treat inflammation while showing excellent effects in relieving itching and reducing pain. Also, a pharmaceutical use of a medical ointment having such novel combination provides a useful effect to solve the problems required in the above prior art.

